Bexxar Related Clinical Trials
A Comparison Of Rituximab vs. Iodine I 131 Tositumomab Therapeutic Regimen (i.e., BEXXAR) For Patients With Relapsed Follicular Non-Hodgkins Lymphoma [Active, not recruiting]
Expanded Access Study Of BEXXAR® For Low Grade And Transformed Low-Grade Non-Hodgkin's Lymphoma [No longer available]
Expanded Access Study of Iodine-131 Anti-B1 Antibody [Active, not recruiting]
Study of Untreated or Transformed Follicular Non-Hodgkin's Lymphoma With Fission-Derived Iodine I 131 Tositumomab [Completed]
Safety and Efficacy Study of Iodine-131 Anti-B1 Antibody for the Retreatment of Patients With Non-Hodgkin's Lymphoma [Active, not recruiting]
Study Looking to See How Effective Fludarabine and Rituximab Followed by Bexxar Are for CLL or SLL [Recruiting]
A Study Of Pharmacokinetics, Whole Body And Organ Dosimetry, And Biodistribution Of Fission-Derived Iodine I 131 Tositumomab (BEXXAR®) For Patients With Previously Untreated Or Relapsed Follicular Or Transformed Non-Hodgkin's Lymphoma [Recruiting]
Comparison of Rituxan Versus Bexxar When Combined With Carmustine, Etoposide, Cytarabine and Melphalan (BEAM) With Autologous Hematopoietic Stem Cell Transplantation (ASCT) [Recruiting]
Study to Treat Relapsed Follicular Non-Hodgkin's Lymphoma With Radiation and Bexxar [Recruiting]
Safety and Efficacy Study of I-131 Tositumomab in Patients With Relapsed/Refractory Hodgkin's Lymphoma [Recruiting]
Safety and Efficacy Study of Iodine-131 Anti-B1 Antibody Plus CHOP For Untreated Mantle Cell Lymphoma [Completed]
Safety and Efficacy of Iodine-131 Anti-B1 Antibody for NHL Patients With Greater Than 25% Bone Marrow Involvement [Active, not recruiting]
Safety and Efficacy of Iodine-131 Anti-B1 Antibody for Intermediate Grade Non-Hodgkin's Lymphoma Following First Line CHOP [Active, not recruiting]
A Comparative Study Of Iodine I 131 Tositumomab Therapeutic Regimen Versus Ibritumomab Tiuxetan Therapeutic Regimen [Withdrawn]
Clinical Trial of Consolidation Treatment With Iodine I 131 Tositumomab for Multiple Myeloma [Recruiting]
Safety and Efficacy of Bexxar Therapy in the Treatment of Relapsed/Residual B-Cell Lymphoma After Autologous Transplant [Recruiting]
Patients With Low-Grade Non-Hodgkin's Lymphoma Previously Treated With Tositumomab and/or Iodine I 131 Tositumomab [Active, not recruiting]
Patients With Low-Grade Non-Hodgkin's Lymphoma Previously Treated With Iodine I 131 Tositumomab [Active, not recruiting]
Safety and Efficacy Study of Iodine-131 Anti-B1 Antibody for Chronic Lymphocytic Leukemia [Active, not recruiting]
A Phase II Trial of Combined Weekly Bortezomib and Tositumomab I-131 in Patients With Relapsed or Refractory Follicular Non-Hodgkin's Lymphoma [Recruiting]
Study of Bexxar Combined With External Beam Radiation Therapy for Patients With Relapsed, Bulky Non-Hodgkin's Lymphoma [Recruiting]
Phase II Study of Bexxar in Relapsed/Refractory Diffuse Large Cell Lymphoma [Recruiting]
Tositumomab And Iodine I 131-Tositumomab In Patients With Relapsed Indolent Non-Hodgkin's Lymphoma [Recruiting]
Iodine I 131 Tositumomab, Rituximab, and Combination Chemotherapy in Treating Older Patients With Stage II, Stage III, or Stage IV Non-Hodgkin's Lymphoma [Recruiting]
A Study of Rituximab Versus Iodine I 131 Tositumomab Therapy for Patients With Non-Hodgkin's Lymphoma [Recruiting]
Iodine I 131 Tositumomab Followed by Autologous Stem Cell Transplantation in Treating Older Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma [Active, not recruiting]
Iodine I 131 Tositumomab and Fludarabine in Treating Older Patients Who Are Undergoing an Autologous Stem Cell Transplant for Relapsed or Refractory Non-Hodgkin's Lymphoma [Recruiting]
Iodine I 131 Tositumomab or Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Non-Hodgkin's Lymphoma [Recruiting]
Iodine I 131 Tositumomab, Etoposide, and Cyclophosphamide Followed by Autologous Stem Cell Transplantation in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma [Recruiting]
Iodine I 131 Tositumomab, Rituximab, and Combination Chemotherapy in Treating Patients With Previously Untreated Stage II, Stage III, or Stage IV Follicular Non-Hodgkin Lymphoma [Not yet recruiting]
Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's Lymphoma [Active, not recruiting]
Monoclonal Antibody Therapy, Combination Chemotherapy, and Peripheral Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma [Active, not recruiting]
Phase 1 Study of Radiosensitization Using Bortezomib for Relapsed Mantle Cell or Aggressive Lymphoma Patients in Radioimmunotherapy [Recruiting]
Chemotherapy With Monoclonal Antibody and Radioimmunotherapy for High-Risk B-Cell Non-Hodgkins Lymphoma [Recruiting]
Combination Chemotherapy Plus Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's Lymphoma [Completed]
Long-Term Effects of Iodine I Tositumomab and Autologous Bone Marrow or Stem Cell Transplantation in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma [Active, not recruiting]
|
